Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Granulosa cell tumour

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Granulosa cell tumour. Displaying page 1 of 1.
    EudraCT Number: 2012-001948-21 Sponsor Protocol Number: GETHI-2011-03 Start Date*: 2012-08-17
    Sponsor Name:Grupo Español de Tumores Huérfanos e Infrecuentes
    Full Title: Open Phase II Study of Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary. GreKo Study.
    Medical condition: Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057376 Ovarian granulosa-theca cell tumour PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003128-35 Sponsor Protocol Number: GETHI-2013-01 Start Date*: 2014-06-05
    Sponsor Name:Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI)
    Full Title: Open label phase II clinical trial of Orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors. The Greko II study.
    Medical condition: Metastatic or advanced non-resectable granulosa cell ovarian tumors
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057376 Ovarian granulosa-theca cell tumour PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001816-25 Sponsor Protocol Number: NIR-OGT-201 Start Date*: 2022-12-07
    Sponsor Name:SpringWorks Therapeutics, Inc.
    Full Title: A Phase 2 trial of Nirogacestat in Patients with Recurrent Ovarian Granulosa Cell Tumors
    Medical condition: Ovarian Granulosa Cell Tumor
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073260 Ovarian granulosa cell tumour PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073273 Ovarian granulosa cell tumor LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003192-11 Sponsor Protocol Number: ANZGOG0903 Start Date*: 2012-09-07
    Sponsor Name:University of Sydney [...]
    1. University of Sydney
    2. University of Sydney
    Full Title: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms
    Medical condition: Women with oestrogen receptor and/or progesterone receptor positive (ER/PR+ve) potentially hormone responsive recurrent or metastatic gynaecological cancer including selected patients with epitheli...
    Disease:
    Population Age: Adults, Elderly Gender:
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004469-10 Sponsor Protocol Number: GETHI-2016-01 Start Date*: 2018-01-22
    Sponsor Name:Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI)
    Full Title: Open label phase II clinical trial of enzalutamide in metastatic or advanced non-resectable granulosa cell ovarian tumors. GreKo III study.
    Medical condition: Advanced ovarian granulosa unresectable or metastatic tumor
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000501-52 Sponsor Protocol Number: PARAGON2011 Start Date*: 2011-12-07
    Sponsor Name:Greater Glasgow and Clyde [...]
    1. Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms
    Medical condition: Patients with potentially hormone responsive recurrent or metastatic gynaecological cancers from following subgroups: A - Epithelial ovarian cancer, primary peritoneal cancers and cancers of the fa...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026310 Malignant neoplasm of ovary LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014760 Endometrial neoplasm malignant LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002841-39 Sponsor Protocol Number: GINECO-OV-222 Start Date*: 2013-10-07
    Sponsor Name:ARCAGY GINECO
    Full Title: A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with rela...
    Medical condition: Patients with an histologically confirmed diagnosis of ovarian sex-cord stromal tumor in relapse after a platinum-based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 13:29:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA